

# FLUBLOK<sup>®</sup> QUADRIVALENT (INFLUENZA VACCINE) FACT SHEET

**Flublok Quadrivalent vaccine** is the only recombinant protein-based influenza vaccine approved by the U.S. Food and Drug Administration (FDA).<sup>i</sup> Flublok Quadrivalent vaccine is approved for use in persons 18 years of age and older.<sup>i</sup>

**Flublok<sup>®</sup>**  
**QUADRIVALENT**  
**Influenza Vaccine**

Sanofi Pasteur recently acquired Protein Sciences that developed Flublok Quadrivalent vaccine, using a **recombinant DNA** technology. This acquisition allows Sanofi Pasteur to offer patients a dual technology platform of traditional egg-based vaccine and vaccine manufactured with recombinant methods (which is non-egg based).

In relation to vaccines, recombinant technology is part of the manufacturing process and is used to rapidly and reliably grow (or propagate) specific parts of the influenza virus that have been identified as key to stimulating immunity against disease. This technology can be used in various kinds of cells (yeast, bacteria, insect, etc.) to potentially improve yields and efficiency.

As adults turn **50 years of age and older**, they are more likely to develop chronic medical conditions and are at higher risk of developing flu-related complications.<sup>ii</sup>

- **70 percent** of adults 50-64 years of age have at least one chronic medical condition and 50 percent have more than one.

In a recent clinical study in adults 50 years of age and older, individuals who received **Flublok Quadrivalent vaccine** were significantly **less likely to get influenza** than those who received a quadrivalent inactivated influenza vaccine.<sup>iii</sup>

**30%** BETTER PROTECTION  
from influenza disease  
PRIMARY ENDPOINT:  
rtPCR<sup>a</sup>-confirmed, protocol-  
defined, influenza-like illness  
due to any influenza virus  
type or subtype<sup>1,2</sup>

**43%** BETTER PROTECTION  
from influenza disease  
SECONDARY ENDPOINT:  
Culture-confirmed, protocol-  
defined, influenza-like illness  
due to any influenza virus  
type or subtype<sup>1,2</sup>

References:

<sup>a</sup> rtPCR = Reverse transcriptase polymerase chain reaction.

<sup>1</sup> Flublok Quadrivalent vaccine [Prescribing Information]. Meriden, CT: Protein Sciences Corporation.

<sup>2</sup> Dunkle LM, Izikson R, Patriarca P, et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. *N Engl J Med.* 2017;376:2427-2436.

### **Important Safety Information for Flublok Quadrivalent Vaccine**

Flublok Quadrivalent vaccine should not be given to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to a previous dose of the vaccine or any component of the vaccine.

Tell your doctor if you have ever experienced Guillain-Barré syndrome (severe muscle weakness) after a previous dose of influenza vaccine. If you notice any other problems or symptoms following vaccination, please contact your health care professional immediately.

The most common side effects to Flublok Quadrivalent vaccine are tenderness and pain at the injection site; headache, fatigue, muscle aches, and joint pain. Other side effects may occur. Vaccination with Flublok Quadrivalent vaccine may not protect all individuals.

### **Indication for Flublok Quadrivalent Vaccine**

Flublok Quadrivalent vaccine is given to people 18 years of age and older to help prevent influenza disease caused by influenza A and B strains contained in the vaccine.

Please see the full Prescribing Information for [Flublok Quadrivalent](#) vaccine.

- 
- i. Warren-Gash C, Hayward AC, Hemingway H, et al. Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. *J Infect Dis.* 2012;206:1652-1659.
  - ii. Centers for Disease Control and Prevention (CDC). People at High Risk of Developing Flu-Related Complications. [https://www.cdc.gov/flu/about/disease/high\\_risk.htm](https://www.cdc.gov/flu/about/disease/high_risk.htm).
  - iii. Dunkle LM, Izikson R, Patriarca P, et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older *NEJM.* 2017;376(25):2427-2436.